Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17133979 | SECO MACROLIDE COMPOUNDS | December 2020 | June 2022 | Allow | 18 | 1 | 1 | No | No |
| 17255810 | PIKfyve Inhibitors | December 2020 | February 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17255821 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | December 2020 | November 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 17130729 | FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER | December 2020 | January 2022 | Allow | 13 | 1 | 0 | No | No |
| 17255351 | IMPROVEMENTS IN SUPERCRITICAL CARBON DIOXIDE EXTRACTION | December 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17127075 | METHODS OF TREATING BRAIN DISORDERS | December 2020 | June 2024 | Allow | 41 | 1 | 1 | No | No |
| 17253939 | PRODRUGS OF NALTREXONE, NALMEFENE AND DERIVATIVES THEREOF | December 2020 | July 2021 | Allow | 6 | 0 | 0 | No | No |
| 17124852 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | December 2020 | August 2021 | Allow | 8 | 0 | 0 | No | No |
| 17253250 | NOVEL NARINGENIN/LIPOIC ACID CONJUGATE COMPOUND AND USE THEREOF | December 2020 | March 2024 | Abandon | 39 | 1 | 0 | Yes | No |
| 17252423 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | December 2020 | January 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17117682 | Silicon-based Tetrahydrocannabinol Derivatives and Compositions Thereof | December 2020 | February 2023 | Allow | 26 | 0 | 1 | No | No |
| 17251035 | METHOD FOR ISOLATION OF AN AROMATIC DIANHYDRIDE AND AROMATIC DIANHYDRIDES PREPARED BY THE METHOD | December 2020 | November 2023 | Allow | 35 | 2 | 1 | No | No |
| 17115037 | Process For Preparing Aminopyrimidine Derivatives | December 2020 | November 2021 | Allow | 11 | 1 | 0 | No | No |
| 17112980 | SMALL MOLECULE INDUCERS OF AUTOPHAGY | December 2020 | March 2022 | Allow | 16 | 0 | 1 | No | No |
| 17108110 | PYRAZOLE DERIVATIVES | December 2020 | July 2022 | Abandon | 19 | 2 | 0 | No | No |
| 17059376 | ANTITUMOR AGENT AND METHOD FOR TUMOR THERAPY | November 2020 | March 2024 | Allow | 40 | 2 | 0 | No | No |
| 17105572 | Compounds and Methods for Inhibiting CPY26 Enzymes | November 2020 | April 2022 | Allow | 16 | 1 | 0 | Yes | No |
| 17058560 | HMF PREPARATION CATALYSED BY ANOLYTE FRACTION | November 2020 | February 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17100528 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE | November 2020 | November 2021 | Allow | 12 | 1 | 0 | No | No |
| 16953112 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH1) | November 2020 | September 2022 | Allow | 22 | 0 | 0 | No | No |
| 17055079 | MAGL INHIBITORS | November 2020 | February 2022 | Allow | 15 | 1 | 0 | No | No |
| 17091001 | AMORPHOUS FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR | November 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 17090160 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | November 2020 | March 2023 | Allow | 28 | 1 | 1 | No | No |
| 17083543 | THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER | October 2020 | March 2022 | Allow | 16 | 1 | 0 | No | No |
| 17083898 | THALIDOMIDE ANALOGS AND METHODS OF USE | October 2020 | May 2022 | Allow | 18 | 2 | 1 | No | No |
| 17048951 | DIMETHYLPHOSPHINE OXIDE COMPOUND | October 2020 | March 2021 | Allow | 5 | 0 | 0 | No | No |
| 17072539 | USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION | October 2020 | December 2021 | Allow | 14 | 1 | 0 | No | No |
| 17073019 | IRAK DEGRADERS AND USES THEREOF | October 2020 | July 2021 | Allow | 9 | 0 | 0 | No | No |
| 17047787 | ANTICANCER INDENES, INDANES, AZAINDENES, AZAINDANES, PHARMACEUTICAL COMPOSITIONS AND USES | October 2020 | July 2021 | Allow | 9 | 0 | 0 | Yes | No |
| 17047475 | Composition for Protecting Cardiomyocyte | October 2020 | February 2024 | Allow | 40 | 1 | 1 | No | No |
| 17047247 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | October 2020 | June 2022 | Allow | 20 | 1 | 1 | No | No |
| 16948966 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | October 2020 | April 2022 | Allow | 19 | 0 | 0 | No | No |
| 17063372 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | October 2020 | October 2021 | Allow | 13 | 1 | 0 | No | No |
| 17062295 | EMETINE AURISTATIN COMPOUNDS | October 2020 | September 2022 | Allow | 23 | 1 | 0 | No | No |
| 17044173 | PHOSPHATE DERIVATIVES AND USE THEREOF | September 2020 | October 2023 | Allow | 37 | 3 | 1 | Yes | No |
| 17043657 | A PROCESS FOR THE PREPARATION OF LIFITEGRAST | September 2020 | February 2022 | Allow | 16 | 1 | 0 | No | No |
| 17042309 | PROCESS FOR THE PREPARATION OF GLYCIDOL | September 2020 | June 2022 | Allow | 20 | 0 | 0 | No | No |
| 17040832 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | September 2020 | September 2021 | Allow | 12 | 1 | 0 | No | No |
| 17022803 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | September 2020 | September 2021 | Allow | 12 | 1 | 0 | No | No |
| 16980757 | PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | September 2020 | November 2020 | Allow | 2 | 0 | 0 | No | No |
| 17019097 | USP30 INHIBITORS AND USES THEREOF | September 2020 | July 2023 | Allow | 34 | 5 | 1 | No | No |
| 17015625 | COMPOSITIONS AND METHODS OF TREATING NEURONAL INJURY | September 2020 | March 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 16977444 | GRACILIN A AND CONGENERS AS IMMUNOSUPPRESSIVE AND NEUROPROTECTIVE AGENTS | September 2020 | March 2021 | Allow | 6 | 1 | 0 | No | No |
| 16977093 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | August 2020 | October 2022 | Allow | 25 | 2 | 0 | No | No |
| 17005727 | PAIN RELIEVING FORMULATIONS CONTAINING CANNABIS AND METHODS OF MAKING SAME | August 2020 | August 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16993821 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | August 2020 | November 2020 | Allow | 4 | 1 | 0 | No | No |
| 16991268 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | August 2020 | December 2020 | Allow | 5 | 1 | 0 | No | No |
| 16969290 | SYNTHETIC RECEPTORS FOR IONOPHORIC COMPOUNDS | August 2020 | November 2022 | Allow | 27 | 1 | 1 | No | No |
| 16983701 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | August 2020 | December 2020 | Allow | 4 | 1 | 0 | No | No |
| 16943649 | OXYSTEROLS AND METHODS OF USE THEREOF | July 2020 | December 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16922355 | USE OF IMMUNE MODULATORS TO IMPROVE NERVE REGENERATION | July 2020 | December 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16921010 | Water Soluble Cannabinoid Product with Reduced Particle Size for Enhanced Delivery | July 2020 | April 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16959536 | ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME | July 2020 | August 2022 | Allow | 26 | 1 | 0 | No | No |
| 16958618 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | June 2020 | July 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16958225 | METHOD FOR PRODUCING THIOCARBOXAMIDINE SALT COMPOUND | June 2020 | September 2020 | Allow | 3 | 0 | 0 | No | No |
| 16911358 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | June 2020 | July 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16910708 | THALIDOMIDE ANALOGS AND METHODS OF USE | June 2020 | July 2020 | Allow | 1 | 0 | 0 | No | No |
| 16909543 | NOVEL GPR119 AGONIST COMPOUNDS | June 2020 | November 2020 | Allow | 5 | 1 | 0 | No | No |
| 16908487 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | June 2020 | January 2021 | Allow | 7 | 1 | 0 | No | No |
| 16956871 | KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | June 2020 | September 2023 | Allow | 39 | 3 | 1 | No | No |
| 16956432 | NEW COMPOSITION OF LIPOAMINO ACIDS AND ALKANEDIOLS, PROCESS FOR THE PREPARATION THEREOF, AND COSMETIC OR PHARMACEUTICAL COMPOSITION RESULTING THEREFROM | June 2020 | November 2022 | Allow | 29 | 0 | 1 | No | No |
| 16905667 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | June 2020 | December 2020 | Allow | 6 | 2 | 1 | Yes | No |
| 16955240 | 3-(5-AMINO-PYRAZIN-2-YL)-BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PI3K-GAMMA KINASE INHIBITORS | June 2020 | January 2022 | Allow | 19 | 0 | 0 | No | No |
| 16772044 | PHARMACEUTICAL COMPOSITIONS OF TEDIZOLID PHOSPHATE | June 2020 | May 2022 | Allow | 23 | 0 | 0 | No | No |
| 16770273 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | June 2020 | November 2022 | Allow | 29 | 1 | 1 | No | No |
| 16769557 | PROCESS FOR PREPARING ETHYLENE CARBONATE AND ETHYLENE GLYCOL USING AN ALKYL IODIDE GUARD BED SYSTEM | June 2020 | January 2023 | Allow | 32 | 1 | 0 | No | No |
| 16889780 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | June 2020 | August 2021 | Allow | 15 | 1 | 0 | No | No |
| 16768616 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | May 2020 | February 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16887785 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | May 2020 | February 2022 | Abandon | 20 | 0 | 1 | No | No |
| 16767056 | SQUARYLIUM COMPOUNDS FOR USE IN DISPLAY DEVICES | May 2020 | April 2022 | Allow | 23 | 0 | 1 | No | No |
| 16766314 | BENZOIC ACID, OR A SALT OR DERIVATIVE THEREOF FOR USE IN PREVENTING OR TREATING DEPRESSION | May 2020 | December 2022 | Allow | 31 | 2 | 0 | No | No |
| 16877593 | Novel Amide Compounds and Use Thereof | May 2020 | July 2021 | Allow | 14 | 1 | 0 | No | No |
| 16878010 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | May 2020 | February 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 16765393 | PROCESS FOR THE PREPARATION OF PIPERINE | May 2020 | October 2021 | Allow | 17 | 0 | 0 | No | No |
| 16874715 | Enantioselective Process For Manufacture | May 2020 | June 2020 | Allow | 1 | 0 | 0 | No | No |
| 16764033 | NEW SALT AND SOLID STATE FORMS OF ESCITALOPRAM | May 2020 | March 2022 | Allow | 22 | 1 | 0 | No | No |
| 16874136 | Pyrazole Derivatives | May 2020 | May 2020 | Allow | 0 | 0 | 0 | No | No |
| 16874165 | Enantioselective Process For The Manufacture Of Lactam Carboxylate Derivatives | May 2020 | June 2020 | Allow | 1 | 0 | 0 | No | No |
| 16869794 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | May 2020 | October 2020 | Allow | 5 | 1 | 0 | No | No |
| 16870777 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | May 2020 | January 2021 | Allow | 8 | 1 | 0 | No | No |
| 16762493 | METHOD FOR PRODUCING PHOSPHORUS CHEMICALS FROM WET PROCESS PHOSPHATE | May 2020 | January 2024 | Allow | 44 | 2 | 1 | No | No |
| 16868624 | CRYSTALS OF INTERMEDIATE FOR BENZINDENE PROSTAGLANDINS AND METHODS FOR PREPARATION THEREOF | May 2020 | July 2020 | Allow | 3 | 1 | 0 | No | No |
| 16863867 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | April 2020 | May 2022 | Allow | 25 | 4 | 1 | No | No |
| 16760345 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | April 2020 | May 2022 | Allow | 24 | 1 | 1 | No | No |
| 16859121 | ANTIVIRAL AGENTS FOR DRUG-RESISTANT INFLUENZA A | April 2020 | July 2021 | Allow | 14 | 2 | 1 | Yes | No |
| 16759159 | ENTECAVIR INTERMEDIATE, SYNTHETIC METHOD THEREOF AND SYNTHETIC METHOD FOR ENTECAVIR | April 2020 | April 2021 | Allow | 12 | 1 | 0 | Yes | No |
| 16758085 | Compounds Useful in HIV Therapy | April 2020 | November 2021 | Allow | 19 | 0 | 0 | No | No |
| 16757326 | PROCESS FOR THE HALOGENATION AT THE ALPHA-H POSITION OF ALKYLARENES VARIOUSLY SUBSTITUTED ON THE AROMATIC RING | April 2020 | July 2021 | Allow | 15 | 0 | 0 | Yes | No |
| 16756083 | DEUTERATED AZOLE COMPOUNDS AND PREPARATION METHOD THEREFOR AND USES THEREOF | April 2020 | August 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16755346 | OLEACEIN FOR USE IN ATHEROSCLEROSIS PREVENTION | April 2020 | September 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16754814 | NEURAMINIDASE INHIBITION TO IMPROVE GLYCOCALYX VOLUME AND FUNCTION TO AMELIORATE CARDIOVASCULAR DISEASES IN PATHOLOGIES ASSOCIATED WITH GLYCOCALYX DAMAGE | April 2020 | February 2023 | Allow | 34 | 2 | 1 | No | No |
| 16841444 | COMPOUNDS INHIBITING NEF-CALNEXIN INTERACTION | April 2020 | May 2021 | Allow | 13 | 1 | 1 | No | No |
| 16753243 | ANTIBACTERIAL MONOBACTAMS | April 2020 | April 2022 | Allow | 24 | 1 | 0 | No | No |
| 16652956 | SOLVENT COMPOUNDS FOR USE AS GLYCOL ETHER REPLACEMENTS | April 2020 | December 2020 | Allow | 8 | 1 | 0 | No | No |
| 16832034 | ROSIN-BASED SMALL MOLECULAR WEIGHT HYDROGELATOR AND ITS APPLICATION | March 2020 | March 2022 | Allow | 23 | 0 | 0 | No | No |
| 16651260 | NEW DERIVATES OF DHAA WITH ELECTROSTATIC TUNING | March 2020 | June 2023 | Abandon | 39 | 3 | 1 | No | No |
| 16649756 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-1) ANTIBODIES AND A CXCR2 ANTAGONIST | March 2020 | May 2021 | Allow | 14 | 1 | 0 | No | No |
| 16649831 | METHOD FOR REGENERATING CATALYST AND METHOD FOR PRODUCING CARBONATE ESTER | March 2020 | December 2022 | Allow | 33 | 1 | 1 | No | No |
| 16648570 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | March 2020 | February 2022 | Allow | 23 | 1 | 1 | No | No |
| 16820096 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | March 2020 | May 2022 | Abandon | 26 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VAJDA, KRISTIN ANN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner VAJDA, KRISTIN ANN works in Art Unit 1626 and has examined 889 patent applications in our dataset. With an allowance rate of 84.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 16 months.
Examiner VAJDA, KRISTIN ANN's allowance rate of 84.4% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by VAJDA, KRISTIN ANN receive 0.94 office actions before reaching final disposition. This places the examiner in the 6% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by VAJDA, KRISTIN ANN is 16 months. This places the examiner in the 97% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +9.1% benefit to allowance rate for applications examined by VAJDA, KRISTIN ANN. This interview benefit is in the 40% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 41.9% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 75.9% of cases where such amendments are filed. This entry rate is in the 95% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.0% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.